Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term survival after continuous infusion interleukin-2.

R O Dillman1, C Church, N M Barth

  • 1Patty and George Hoag Cancer Center, Newport Beach, California 92658, USA.

Cancer Biotherapy & Radiopharmaceuticals
|August 1, 1997
PubMed
Summary

High-dose interleukin-2 (IL-2) therapy showed a 6% to 20% 3-year survival rate in metastatic cancers. Objective tumor response significantly correlated with improved long-term survival, highlighting IL-2's potential in select patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left ventricular dysfunction and intra-ventricular dyssynchrony in idiopathic pulmonary arterial hypertension.

International journal of cardiology·2022
Same author

<i>In vitro</i> characterization of the effects of chronic insulin stimulation in mouse 3T3-L1 and human SGBS adipocytes.

Adipocyte·2020
Same author

Patient-reported mobility function and engagement in young adults with cerebral palsy: a cross-sectional sample.

Journal of children's orthopaedics·2018
Same author

Flexed-knee gait in children with cerebral palsy: a long-term follow-up study.

The bone & joint journal·2018
Same author

Longitudinal change in foot posture in children with cerebral palsy.

Journal of children's orthopaedics·2017
Same author

Hyperconnectivity in juvenile myoclonic epilepsy: a network analysis.

NeuroImage. Clinical·2015

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • High-dose continuous intravenous interleukin-2 (IL-2) was administered to 612 patients in National Biotherapy Study Group (NBSG) phase II trials between 1987-1990.
  • This analysis focuses on long-term survival outcomes and the relationship between tumor response and survival following IL-2 treatment.

Purpose of the Study:

  • To determine the long-term survival rates associated with high-dose continuous intravenous IL-2 therapy.
  • To investigate the correlation between objective tumor response and survival in patients treated with IL-2.

Main Methods:

  • Identification of patients surviving at least 3 years post-IL-2 initiation.
  • Calculation of actual and actuarial survival rates stratified by malignancy type and tumor response.

Main Results:

Related Experiment Videos

  • At least 6.0% of patients survived over 3 years, with a potential 3-year survival rate as high as 20%.
  • Objective response rates (complete or partial response) were 9%, with a 15% total response rate including mixed responses.
  • Three-year survival rates were significantly higher for responders (17%) compared to stable disease (8%) and progressive disease (2%).
  • Patients with objective tumor responses had a substantially higher likelihood of surviving beyond 3 years compared to non-responders (17% vs. 4%).

Conclusions:

  • Interleukin-2 therapy demonstrated a significant improvement in 3-year survival for responders and those with stable disease compared to progressive disease.
  • Actual 3-year survival rates of 6% to 8% were observed in patients with metastatic melanoma and renal cell carcinoma, even after standard therapy failure.